Concentrations of protease inhibitors in cord blood after in utero exposure

Mark Mirochnick(Boston University), John L. Sullivan, Alex Dorenbaum(BCS — The Chartered Institute for IT), Mary Culnane(National Institute of Allergy and Infectious Diseases), Richard D. Gelber(Harvard University), James D. Connor, Colleen Cunningham(BCS — The Chartered Institute for IT), Diane Holland(BCS — The Chartered Institute for IT), Lynne Mofenson(Elizabeth Glaser Pediatric AIDS Foundation), BETHANN CUNNINGHAM-SCHRADER(BCS — The Chartered Institute for IT)
The Pediatric Infectious Disease Journal
September 1, 2002
10.1097/00006454-200209000-00010
Cited by 60

Related Papers

Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k
Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis
|BMJ|2020|2.4k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
|The Lancet|1999|1.7k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k